title: Emotion processing in schizophrenia: fMRI study of patients treated with risperidone long-acting injections or conventional depot medication.
abstract: We employed two event-related functional magnetic resonance imaging tasks using the pictures of mild and intense facial emotions of fear or happiness. The sample comprised 16 chronic schizophrenia patients treated with risperidone long-acting injections (RLAI), 16 patients treated with conventional antipsychotic depots (CONV) and 16 healthy controls (HC). The HC and RLAI groups demonstrated greater activation in the left amygdala in response to intensively fearful faces, and in right cerebellum to intensively happy faces compared with CONV patients. The CONV group demonstrated under-activation in the right temporal pole in response to intensively happy faces (compared with HC) and over-activation in ventro-medial prefrontal cortex (VMPFC) in response to both intensively happy and fearful expressions, compared with HC and RLAI groups. Our results suggest that networks implicated in the allocation of attentional resources (VMPFC) and emotion processing (amygdala, cerebellum) are differentially affected in patients on CONV versus RLAI.
authors.affiliation: Division of Psychological Medicine and Psychiatry, King's College London Institute of Psychiatry, London, UK. simon.2.surguladze@kcl.ac.uk
authors.forename: Simon A
authors.initials: SA
authors.lastname: Surguladze
authors.forename: Elvina M
authors.initials: EM
authors.lastname: Chu
authors.forename: Nicolette
authors.initials: N
authors.lastname: Marshall
authors.forename: Anthony
authors.initials: A
authors.lastname: Evans
authors.forename: Anantha P P
authors.initials: AP
authors.lastname: Anilkumar
authors.forename: Clive
authors.initials: C
authors.lastname: Timehin
authors.forename: Colm
authors.initials: C
authors.lastname: McDonald
authors.forename: Christine
authors.initials: C
authors.lastname: Ecker
authors.forename: Mary L
authors.initials: ML
authors.lastname: Phillips
authors.forename: Anthony S
authors.initials: AS
authors.lastname: David
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D001288:Attention / Q000187:drug effects / Q000502:physiology; D001921:Brain / Q000187:drug effects / Q000503:physiopathology; D001931:Brain Mapping / Q000379:methods; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000627:therapeutic use; D004644:Emotions / Q000187:drug effects* / Q000502:physiology*; D005149:Facial Expression; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008875:Middle Aged; D010775:Photic Stimulation; D011597:Psychomotor Performance / Q000187:drug effects / Q000502:physiology; D018967:Risperidone / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology*; D012565:Schizophrenic Psychology
chemical_list: D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D018967:Risperidone